1

The asymptomatic proportion of SARS-CoV-2 Omicron variant infections in households: A systematic review

4

Nancy DJ Shi^{1,*}, Adrian J Marcato^{1,*}, Violeta Spirkoska¹, Niamh Meagher¹, Juan-Pablo
 Villanueva-Cabezas^{1,2}, David J Price^{1,3,†}

7 8

¹ Department of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute
 for Infection and Immunity, Melbourne, Victoria, 3000, Australia

² The Nossal Institute for Global Health, The University of Melbourne, Melbourne, Victoria, 3000,
 Australia

- ¹³ ³Centre for Epidemiology & Biostatistics, Melbourne School of Population & Global Health, The
- 14 University of Melbourne, Melbourne, Victoria, 3000, Australia
- 15
- 16 * These authors contributed equally
- 17 [†] Email correspondence to: <u>david.price1@unimelb.edu.au</u>
- 18
- 19
- 20

21 Abstract

22 23

Background

24 Understanding the clinical spectrum of SARS-CoV-2 infection, including the asymptomatic fraction, is important as asymptomatic individuals are still able to infect 25 other individuals and contribute to ongoing transmission. The WHO Unity Household 26 transmission investigation (HHTI) protocol provides a platform for the prospective and 27 28 systematic collection of high-quality clinical, epidemiological, serological, and virological 29 data from SARS-CoV-2 confirmed cases and their household contacts. These data can be used to understand key severity and transmissibility parameters — including the 30 asymptomatic proportion — in relation to local epidemic context and help inform public 31 32 health response. 33 **Methods** 34

We aimed to estimate the asymptomatic proportion of SARS-CoV-2 Omicron-variant infections in Unity-aligned HHTIs. We conducted a systematic review and meta-analysis in alignment with the PRISMA 2020 guidelines and registered our systematic review on PROSPERO (CRD42022378648). We searched EMBASE, Web of Science, MEDLINE, and bioRxiv and medRxiv from 1 November 2021 to 22 August 2023.

40

41 Results

42 We identified 8,368 records, of which 98 underwent full text review. We identified only

three studies for data extraction, with substantial variation in study design and

44 corresponding estimates of the asymptomatic proportion. As a result, we did not

45 generate a pooled estimate or l^2 metric.

46 Conclusions

47 The limited number of quality studies that we identified highlights the need for improved

48 preparedness and response capabilities to facilitate robust HHTI implementation,

49 analysis and reporting, to better inform national, regional and global risk assessments

- 50 and policy making.
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58

59

61 Key words

62 Asymptomatic proportion, household transmission, SARS-CoV-2, COVID-19

63

64 Key messages

- Estimates for the asymptomatic proportion of SARS-CoV-2 Omicron-variant infections are highly heterogeneous.
- We assessed the proportion of SARS-CoV-2 Omicron-variant infections among
 household contacts, who were followed prospectively and systematically, per the
 WHO Unity household transmission investigation protocol.
- Given the small number of studies with sufficient data and the observed
 heterogeneity in the asymptomatic proportion point estimates, we did not provide
 a pooled estimate of the asymptomatic proportion.
- Fit-for-purpose study designs, and improved reporting, are necessary for robust
 estimation of epidemiological characteristics from household studies and their
 interpretation.
- Ongoing assessment of the asymptomatic proportion of SARS-CoV-2 infection is
 critical to inform ongoing public health response options such as testing strategies
 to detect infections and isolation guidance for close contacts.

80 Introduction

81

82 Sub-lineages of the SARS-CoV-2 Omicron variant of concern (VOC) continue to

circulate globally and cause significant waves of transmission in the context of hybrid

immunity from coronavirus disease 2019 (COVID-19) vaccination and infection.(1, 2)

85 Although the Omicron-variant is associated with reduced disease severity relative to

86 previous variants, it can still cause serious disease due to its ability to evade existing

87 immunity.(3, 4)

88

89 Studies have shown that the viral load in the upper respiratory tracts of asymptomatic

⁹⁰ infected persons is comparable to that of symptomatic individuals, thus these individuals

91 potentially contribute to onward transmission.(5-7) Asymptomatic individuals may be

less likely to be indicated for or willing to test for infection, and rapid antigen tests

93 (RATs) have been shown to have reduced diagnostic sensitivity in asymptomatic

94 persons.(8-10) Further, individuals with asymptomatic infections may be less likely to

95 practice social or physical distancing measures — due to not knowing they are infected

and potentially infectious — and thus may contribute to the spread of infection in the

97 general population.(11)

98

The asymptomatic proportion among SARS-CoV-2 Omicron-positive individuals has 99 100 previously been estimated in two systematic reviews to be 32.4% (95% CI: 25.3–39.5%, l^2 =97.7%) and 25.5% (95% CI: 17.0–38.2%, l^2 =100%.(12, 13) Both reviews collated 101 and synthesised data from various study designs, including cross-sectional studies that 102 assessed symptom status at a single time point. Cross-sectional studies may lead to 103 104 incorrect classification of presymptomatic individuals as asymptomatic — resulting in a biased estimate of the asymptomatic proportion — and could subsequently contribute to 105 the high degree of observed heterogeneity when combined with estimates from 106 sufficient study designs. Inclusion of such studies in a pooled estimate may lead to an 107 overestimate of the asymptomatic proportion. Such evidence used for informing policy 108 could lead to suboptimal testing of asymptomatic close contacts. 109 110

In 2020, the World Health Organization (WHO) developed the Unity Studies Early 111 Investigation Protocols, to generate high-quality data to inform actions at the beginning 112 113 of the COVID-19 pandemic.(14) One of the Unity protocols — for household transmission investigations (HHTIs) — provides a methodology for the systematic 114 recruitment and longitudinal follow up of laboratory-confirmed SARS-CoV-2 cases and 115 their household contacts, and collection of clinical, virological and serological data.(15) 116 117 Systematic diagnostic testing and symptom data collection are needed to accurately ascertain infection events necessary to estimate the asymptomatic proportion of SARS-118 CoV-2 infection. 119

120	
121	Our systematic review aimed to collate and synthesise the proportion of asymptomatic
122	infections amongst household contacts of SARS-CoV-2 Omicron-variant positive cases,
123	reported in studies aligned with the WHO Unity HHTI protocol. More specifically, we
124	aimed to: identify and describe the implementation of HHTIs in time and place during
125	SARS-CoV-2 Omicron-variant outbreaks; assess the methodological quality of included
126	WHO-aligned HHTIs; calculate a pooled estimate of the asymptomatic proportion of
127	SARS-CoV-2 Omicron-variant infections amongst household contacts, if appropriate,
128	and; explore sources of heterogeneity in the included HHTIs.
129	
130	
131	Methods
132	
133	The systematic review protocol was registered on PROSPERO (CRD42022378648)
134	and was conducted according to the Preferred Reporting Items for Systematic Reviews
135	and Meta-Analyses (PRISMA) reporting guidelines.(16)
136	
137	Definitions
138	
139	Asymptomatic SARS-CoV-2 infections were defined as infections confirmed through an
140	appropriate diagnostic test — e.g., reverse transcriptase polymerase chain reaction
141	(RT-PCR), or rapid antigen test (RAT) — where the individual experienced no
142	symptoms consistent with the clinical case definition of COVID-19 (as defined by
143	included studies in Supplementary Table 1). The asymptomatic proportion was defined
144	as the number of asymptomatic secondary cases amongst all reported secondary cases
145	in households.
146	
147	Note that we include all cases in our estimate of the asymptomatic proportion besides
148	the case that triggered recruitment to the study (i.e., the index case) — this was to avoid
149	the potential bias that would result from a higher propensity for symptoms amongst the
150	index cases.
151	
152	Search strategy
153	
154	MEDLINE, EMBASE and Web of Science databases were searched to identify articles
155	published between 1 November 2021 and 22 August 2023. We searched combinations
156	of COVID-19, asymptomatic, household contacts, and Omicron (including Pango
157	lineages BA.1, BA.2, BA.4 and BA.5). The medRxiv and bioRxiv preprint servers were
158	also searched using the same search criteria. The detailed search strategies can be
159	found in Supplementary Section S.1.

160	
161	Eligibility criteria
162	
163	We included any published (peer-reviewed) or preprint article aligned with the WHO
164	Unity HHTI protocol, involving five or more households, where household contacts were
165	systematically tested for SARS-CoV-2 using an appropriate diagnostic test and had
166	sufficient symptom data collected at more than one time point (i.e., not including cross-
167	sectional studies). Only articles published in English were included.
168	, , , , , , , , , , , , , , , , , , , ,
169	Studies must have reported the proportion of asymptomatic or symptomatic infections
170	amongst household contacts exposed to an index case of the Omicron-variant with a
171	measure of uncertainty (e.g., confidence interval) or provided sufficient data to calculate
172	these parameters.
173	·
174	Screening and article selection
175	
176	Records were imported into Covidence for de-duplication, storage, screening, and data
177	extraction.(17) Records were screened by title and abstract by two independent
178	reviewers (NS, AM) blinded to each other's assessments, and a third independent
179	reviewer (VS) resolved any conflicts. The same methods were applied to the full text
180	screening.
181	
182	Data extraction
183	
184	The following data fields were extracted using a structured and piloted form:
185	investigation timing and duration of follow-up; definition of "household"; definition of
186	"asymptomatic infection"; secondary case ascertainment methods; symptom data
187	collection methods, and the number of index cases, households, household contacts,
188	secondary cases, and asymptomatic secondary cases.
189	
190	Where the reported estimates or definitions were unclear or not provided, study
191	corresponding authors were contacted to request clarification or additional information.
192	Investigations were excluded if authors did not respond after two email attempts over a
193	four-week period.
194	
195	Methodological quality assessment
196	
197	A critical appraisal tool for HHTIs was applied to the included investigations to assess
198	their methodological quality.(18) Two independent reviewers (NS, AM) applied the
199	critical appraisal tool and responses for each question were recorded as yes, no, or

200 unclear. Each investigation was then determined to have a high, moderate, or low 201 overall risk of bias.

- 202
- 203 Data synthesis and statistical analysis
- Estimates of the SARS-CoV-2 asymptomatic proportion and associated 95%
- 205 confidence intervals were extracted from included articles or calculated from the raw
- data. Data cleaning and collation was performed using R version 4.0.(19)
- 207

208 **Results**

209

- Figure 1 summarises the literature search and screening process. We identified 8,368
- records from the research databases and preprint servers, of which 3,770 were
- duplicates. Full text review was undertaken on 98 records. Three studies met our
- inclusion criteria and were retained for data extraction. Details of the reasons for
- exclusion are included in Figure 1.
- The three included studies were all based in the United States of America and were
- conducted from November 2021 to March 2022. (20-22)
- The estimates of the asymptomatic proportion from these three studies vary
- substantially, with point estimates of 0%, 6.7% and 47.8% (Figure 2). Further, these
- estimates were based on small sample sizes the largest including 45 secondary
- cases. As a result, there is substantial uncertainty in each estimate, with the confidence
- intervals spanning 0–69.4%. Given the small number of included studies, we do not
- report a pooled estimate. Further, we have not calculated the l^2 metric, due to its
- 223 unreliability when the number of studies included is small.(20)







Table 1. Summary characteristics of studies included in the systematic review of the asymptomatic proportion of SARS-CoV-2 Omicron-variant infections in households.

Author, Year (ref)	Country	Relevant study period	Case ascertainment methods	Household contact testing strategy	Total number of household secondary cases	Total number of asymptomatic household secondary cases
Smith-		00 NL 1 0004				
Jeffcoat	United	30 November 2021				
et al.,	States of	– 20 December	RT-PCR and			
2022 (21)	America	2021	RAT	Unclear [#]	6	0
				1) 'MHome' cohort - Days 0, 5, and 10 after enrolment for all participating household members.		
Bendall et al., 2022 (22)	United States of America	1 November 2021 ⁺ – 19 January 2022	RT-PCR	2) 'HIVE' cohort - Days 0, 5, and 10 after the index case diagnosis	23	11
	United		RAT once daily upon			
Ji et al.,	States of	November 2021 –	enrolment or	Daily upon		
2023 (23)	America	March 2022	RT-PCR	enrolment	37	3

^{*} Reported median symptom duration of 13 days among positive household contacts implies longitudinal data collection.

236 *Note that this study commenced on November 18, 2020. The reported dates relate to the identification of Omicron-variant infections, as relevant to this study.

238



- 239
- 240

Figure 2. Forest plot of the asymptomatic proportion among household secondary

cases. The estimated asymptomatic proportion and 95% confidence interval (CI) are

shown on the right. Note: Smith-Jeffcoat et al., has a 97.5% confidence Cl as zero

asymptomatic infection events were observed.

246 Smith-Jeffcoat et al. (2022)

247 Smith-Jeffcoat et al., (2022) recruited index cases from attendees at a convention in

- New York City, USA, which was held between 19 and 21 November 2021.(21) SARS-
- 249 CoV-2 infections in attendees were identified using a combination of RT-PCR and
- 250 RATs. Although the exact duration of follow-up was unclear, the investigators stated
- that median symptom duration was 13 days, implying that participants were followed for
- 252 more than 13 days.

245

- In total, 16 index cases (households) were identified who had 20 household contacts. Of
- these, six became secondary cases all six cases were symptomatic during their
 infection.
- Most participants 100% (16/16) of index cases and 95% (19/20) of household
- 257 contacts completed their primary COVID-19 vaccine series more than 14 days prior
- to the study. Additionally, 38% (6/16) of index cases and 53% (10/19) of household
- contacts had received a booster dose.

260 Bendall et al. (2022)

Bendall et al., (2022) recruited households in South-East Michigan, USA between

November 1 2021 and January 19 2022.(22) Household were recruited into two cohorts,

263 known as 'MHome' and 'HIVE'. Participants in both cohorts were tested using RT-PCR

at three timepoints during the investigation on Days 0, 5, and 10 after enrolment

- 265 ('MHome') or after the index case diagnosis ('HIVE').
- In total, 14 index cases (households) were identified, with 24 household contacts.
- Twenty-three household contacts became secondary cases, 11 of which remained asymptomatic after follow-up.
- No vaccination information of householders was provided, however, 54.4% of the
- 270 population in Michigan had completed their primary series of COVID-19 vaccinations by
- 271 November 2021.(24)
- 272 Ji et al. (2023)
- Ji et al., (2023) recruited households through the California Institute of Technology in
- California, USA, between November 2021 and March 2022.(23) Only household
- 275 members aged 6 years and older were included. Household contacts were tested daily
- using RATs as well as providing symptom information. 96% of participants were
- screened for at least 5 days and 53% were enrolled for at least 9 days.
- In total, 28 index cases (households) were identified. An additional five households
 were recruited, where the infecting SARS-CoV-2 variant was inferred to be Omicron

based on local predominance. The 33 index cases were associated with 130 household
 contacts (of which 109 related to the Omicron-variant confirmed households). Forty-five
 household contacts of Omicron-variant confirmed cases became secondary cases, and

- 283 out of 37 secondary cases with complete symptom data, three remained asymptomatic
- until the end of follow-up.

285 31.3% (51/163) of participants (Omicron confirmed and inferred) received their primary

COVID-19 vaccine series more than 7 days prior to the study, with 44.2% (72/163)

- receiving an additional booster dose. A further 3.7% (6/163) of participants were either
- unvaccinated or partially vaccinated (one dose), and the vaccination status was
- unknown for 20.9% (34/163) of participants. The incomplete symptom and vaccination
- status data was attributed to incomplete household recruitment, such that enrolled
- 291 householders reported on the symptom status of their household members who chose
- not to directly participate.
- 293

294 **Discussion**

295 This is the first systematic review investigating the asymptomatic proportion of SARS-

- 296 CoV-2 infections in Unity-aligned HHTI studies. We identified three studies conducted in
- the United States from late-2021 to early-2022, with sufficient longitudinal follow-up and
- specimen sampling from household contacts. Effective control of an infectious disease
- requires identification and appropriate management of infectious individuals to prevent
- transmission. Infectious individuals not presenting with symptoms or meeting the clinical
- 301 criteria of a case definition are typically harder to identify, and thus manage. As such,
- 302 quantifying the prevalence of asymptomatic infections is critical to inform effective
- 303 management strategies that do not rely on the presence of symptoms alone.(25)
- The point estimates of the asymptomatic proportion ranged from 0–47.8%. Previously
- ³⁰⁵ published systematic reviews produced pooled estimates of the asymptomatic
- proportion among SARS-CoV-2 Omicron-positive individuals of 32.4% (95% CI: 25.3–
- 307 39.5%) and 25.5% (95% CI: 17.0–38.2%), despite noting high levels of heterogeneity.
- The point estimates of included studies ranged from 1–92%, $l^2 = 97.7\%$ and 4–40%, $l^2 =$
- 100%.(12, 13) As noted above, we do not report a pooled estimate or l^2 metric.
- 310 Two earlier systematic reviews of the ancestral SARS-CoV-2 strain, both published in
- 2020, by *Buitrago-Garcia et al. (26)* and *Byambasuren et al. (27),* included 79 and 13
- 312 outbreak or contact tracing studies respectively, to produce a pooled estimate of the
- asymptomatic proportion. The included studies in each review were highly
- heterogenous, with estimates for the asymptomatic proportion ranging from 1–92%
- (pooled estimate of 19%, 95% CI: 17–25%), and from 4–40% (pooled estimate of 17%,
- 316 95% CI: 14–20%).(26, 27) Although cross-sectional studies were excluded from

evidence synthesis in these reviews, the extent of heterogeneity as measured by l^2 remained high (84% in (27)).

It is crucial to understand and contextualise the differences between studies prior to 319 320 pooling estimates, to ensure each study is providing quality information towards the same quantity. This includes differences in study design (e.g., frequency and method of 321 testing and symptom data collection), as well as any differences in population-level 322 susceptibility (e.g., age-specific differences, or protection acquired through COVID-19 323 vaccination and/or SARS-CoV-2 infection), or public health and social measures (e.g., 324 325 physical distancing or use of PPE and testing accessibility), that may influence detection 326 of infection and extent of clinical disease. It may be that these differences contributed to the heterogeneity we observed in our three included studies. 327

We focused on household studies as a subset of the literature and thus had fewer

- 329 studies suitable for inclusion, where previous reviews covered a broader range of study
- designs. The abundance of literature early in the pandy emic was likely due to the
- global need to accurately characterise the emerging virus as early as possible. Further,
 the expansion of testing and contact tracing capacities in 2020 and 2021 (prior to
- widespread COVID-19 vaccination) would have enabled or improved capacity for
- conducting studies with systematic testing and follow-up of close contacts, including
- 335 HHTIs.

Subsequently, public health strategies shifted to impose less stringent PHSMs than had
 been implemented to-date, relying instead on effective vaccines against disease to
 reduce the burden of COVID-19. The substantial increase in caseloads corresponding
 to the spread of the Omicron-variant overwhelmed public health systems,(28) reducing
 the ability to implement the level of detailed contact-tracing required to generate data for

- ongoing characterisation of COVID-19, including the asymptomatic proportion. This shift
- in priorities was reflected in the literature during our full text review. Many excluded
- 343 records did not estimate or report the asymptomatic proportion or have sufficient follow-
- ³⁴⁴ up or testing strategies to reliably do so. Instead, they often focussed on the effect of
- vaccination on SARS-CoV-2 transmission dynamics, including estimates of secondary
- 346 attack rates and vaccine effectiveness.
- More generally, during the early stages of the pandemic, journals helped to expedite
- 348 COVID-19 research to rapidly and widely disseminate information needed to address
- the global public health crisis. Our search strategy included articles published to 23
- October 2023. Despite nearly being two years since the emergence of Omicron, we only
- found three relevant articles in the literature, which were all conducted in late-2021 to
- early-2022. In addition to changes in public health priorities and capacity to conduct
- 353 HHTIs, changes in the dissemination of COVID-19 studies in scientific journals may
- have also delayed the availability of other, relevant studies at the time of this review. We

tried to account for delays in publication as the pandemic progressed by searching the

- medRxiv and bioRxiv pre-print servers, which were commonly used to rapidly
 disseminate articles prior to publication.
- 358 While we targeted Unity-aligned studies in our review with the aim of improving 359 comparability of studies, there were still differences present in the design and implementation of included studies. For example, age-specific severity and duration of 360 follow-up are both important aspects for measuring and estimating severity indicators, 361 including the asymptomatic fraction. Age-dependent severity has been documented 362 363 extensively for SARS-CoV-2 infections since the ancestral variant.(29) However, 364 reporting of severity indicators such as the asymptomatic fraction, are not routinely adjusted by age – including in the studies in this review. Further, one study did not 365 include children under 6 years of age. The absence of age-adjusted information — and 366 367 other underlying characteristics and/or risk factors — makes it challenging to explore whether differences in cohorts across studies are substantial contributors to the 368 heterogeneity in reported estimates of the asymptomatic fraction. The follow-up duration 369 differed across the three studies — between 5 and at least 13-days post-recruitment of 370 the index case — as well as the frequency of testing and collection of symptom status. 371 372 The incubation period for the Omicron-variant of SARS-CoV-2 has since been estimated in many studies (30-32) — one estimated the median incubation period to be 373 3.8 days (95%Crl 3.5–4.1).(30) If this distribution was observed in participants in our 374 study, it would be expected that only 82.5% (95%Cl 75.5-88.1) of secondary cases 375 376 would present with symptoms by day 5 were they infected at recruitment (and less if infected thereafter). Further, while we defined inclusion based on individuals being 377 classified as secondary cases, the literature often did not distinguish secondary and 378 subsequent cases (or unrelated cases) in transmission chains. As a result, there is an 379 380 increased likelihood that our included studies still incorrectly classified individuals as 381 pre-symptomatic. The design of transmission studies (including HHTIs) to infer epidemiological characteristics of a pathogen should consider the range of possible 382 values each quantity could take. In the case of the asymptomatic fraction, study design 383 384 should consider the generation interval distribution and incubation period distribution to ensure that participants that are infected (possibly after recruitment given ongoing 385 exposure to cases) are followed for sufficiently long to accurately record their symptom 386 status throughout their infection. Where this information is unknown at the time, a 387 conservative approach to defining a sufficient length of follow up should be taken to 388 389 avoid resources wastage where quantities cannot be estimated due to an inappropriate 390 study design.
- In light of lessons learned through the COVID-19 pandemic thus far, WHO have released updated Unity protocols for influenza and pan-respiratory viruses.(33, 34) The
- sampling schedules therein correlate with biological and epidemiological quantities of

each exemplar pathogen to guide appropriate data and specimen collection to inform
 classification of subsequent cases. Modelling studies accounting for uncertainty in these

- 396 quantities in different pathogen scenarios should be undertaken to inform optimal
- 397 sampling schedules.(35-37)

398 The heterogeneous evidence for the asymptomatic proportion used in existing

- 399 systematic reviews for ancestral SARS-CoV-2 and Omicron suggests that study designs
- still need to be standardised for better implementation and reporting across different
- settings and populations. This is a consistent message with a recent review of the
- 402 household secondary attack rate, (38) where similar limitations in study design and
- reporting were identified, which motivated the development of reporting guidelines and
- 404 updates to the WHO protocols.(18, 33, 34)
- Although the Unity Studies were motivated to produce early generation of evidence for
- 406 COVID-19, HHTIs should be used to support ongoing monitoring of epidemiological
- 407 quantities as the COVID-19 pandemic evolves, e.g., during the emergence of Omicron
- subvariants or new VOCs. Ongoing assessment of these quantities is critical so that
- 409 public health response options such as testing strategies to detect infections and
- isolation guidance for close contacts, can be adjusted accordingly.

411 Conclusion

- 412 HHTIs remain a valuable tool to collect data and collate information on key clinical and
- 413 epidemiological data of COVID-19, especially given the continued evolution of SARS-
- 414 CoV-2. The limited number of quality studies that we identified highlights the need for
- improved preparedness and response capabilities to facilitate robust HHTI
- implementation, analysis and reporting, to better inform national, regional and global
- 417 risk assessments and policy making.

418

419 Ethics approval

420 Not required

421 Data availability

- The data underlying this article are available in the article and in its online
- 423 supplementary material.

424 Supplementary Data

425 Supplementary data are available at *IJE* online.

426 Author contributions

- The authors confirm contribution to the paper as follows: study conceptualisation and
- 428 methodology all; investigation NDJS, AM, VS; data curation NDJS, AM;
- visualization NDJS, AM, DJP; supervision AM, VS, JPVC, DJP; writing original
- 430 draft NDJS, AM, DJP. All authors reviewed and edited the draft manuscript and
- 431 approved the final version for publication.

432 Funding

- AJM and DJP are supported by funding from Australian National Health and Medical
- 434 Research Council Partnership (#1195895).

Conflict of interest

Hodcroft EB. CoVariants: SARS-CoV-2 Mutations and Variants of Interest 2021

[15 April 2024]. Available from: https://covariants.org/.

456 **References**

1.

457

458

459 2. World Health Organization. WHO COVID-19 Dashboard 2024 [15 April 2024]. Available from: https://data.who.int/dashboards/covid19/cases?n=o. 460 Bálint G, Vörös-Horváth B, Széchenyi A. Omicron: increased transmissibility and 461 3. decreased pathogenicity. Signal Transduction and Targeted Therapy. 2022;7(1):151. 462 Relan P, Motaze NV, Kothari K, Askie L, Le Polain O, Van Kerkhove MD, et al. 463 4. Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant 464 and severity of Omicron sublineages: a systematic review and metanalysis. BMJ Glob 465 466 Health. 2023;8(7). Wu Q, Shi L, Li H, Huang S, Li H, Li L, et al. Viral RNA Load in Symptomatic and 5. 467 Asymptomatic COVID-19 Omicron Variant-Positive Patients. Can Respir J. 468 469 2022;2022:5460400. Jiang L, Tang L, Zhu L, Zhu Y, Yang S, Chen W, et al. Viral dynamics during 470 6. 471 SARS-CoV-2 omicron infection highlight presymptomatic and asymptomatic 472 infectiousness. J Infect. 2023;86(5):537-9. Bae S, Kim JY, Lim SY, Park H, Cha HH, Kwon JS, et al. Dynamics of Viral 473 7. 474 Shedding and Symptoms in Patients with Asymptomatic or Mild COVID-19. Viruses. 475 2021;13(11). Fernandez-Montero A, Argemi J, Rodríguez JA, Ariño AH, Moreno-Galarraga L. 476 8. Validation of a rapid antigen test as a screening tool for SARS-CoV-2 infection in 477 asymptomatic populations. Sensitivity, specificity and predictive values. 478 EClinicalMedicine. 2021;37:100954. 479 Venekamp RP, Schuit E, Hooft L, Veldhuijzen IK, van den Bijllaardt W, Pas SD, 480 9. et al. Diagnostic accuracy of SARS-CoV-2 rapid antigen self-tests in asymptomatic 481 individuals in the omicron period: a cross-sectional study. Clinical Microbiology and 482 Infection. 2023;29(3):391.e1-.e7. 483 Schuetz Audrey N, Hemarajata P, Mehta N, Campbell S, Mitchell S, Palavecino 484 10. E, et al. When Should Asymptomatic Persons Be Tested for COVID-19? Journal of 485 Clinical Microbiology. 2020;59(1):10.1128/jcm.02563-20. 486 Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. 487 11. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA Network 488 489 Open. 2021;4(1):e2035057-e. Shang W, Kang L, Cao G, Wang Y, Gao P, Liu J, et al. Percentage of 490 12. Asymptomatic Infections among SARS-CoV-2 Omicron Variant-Positive Individuals: A 491 Systematic Review and Meta-Analysis. Vaccines (Basel). 2022;10(7). 492 Yu W, Guo Y, Zhang S, Kong Y, Shen Z, Zhang J. Proportion of asymptomatic 493 13. 494 infection and nonsevere disease caused by SARS-CoV-2 Omicron variant: A systematic review and analysis. J Med Virol. 2022;94(12):5790-801. 495 496 14. World Health Organization. Coronavirus disease (COVID-19) technical guidance: 497 The Unity Studies: Early Investigation Protocols 2020 [15 April 2024]. Available from: https://www.who.int/emergencies/diseases/novel-498 499 coronavirus-2019/technical-guidance/early-investigations.

15. World Health Organization. Household transmission investigation protocol for

coronavirus disease (COVID-19), version 2.2 2021 [15 April 2024]. Available from:
 https://www.who.int/publications/i/item/household-transmission-investigation-protocol-

502 <u>https://www.who.int/publications/i/item/household-transmission-investigation-protocol-</u>
 503 <u>for-2019-novel-coronavirus-(2019-ncov)-infection</u>.

- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.
 The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
 BMJ. 2021;372:n71.
- 507 **17.** Covidence systematic review software VHI, Melbourne, Australua. [Available 508 from: <u>www.covidence.org</u>.
- Price DJ, Spirkoska V, Marcato AJ, Meagher N, Fielding JE, Karahalios A, et al.
 Household transmission investigation: Design, reporting and critical appraisal. Influenza
 and Other Respiratory Viruses. 2023;17(6):e13165.
- 19. R Core Team. R: A language and environment for statistical computing. R
- 513 Foundation for Statistical Computing, Vienna, Austria. 2021.
- 514 20. von Hippel PT. The heterogeneity statistic I2 can be biased in small meta-
- analyses. BMC Medical Research Methodology. 2015;15(1):35.
- 516 21. Smith-Jeffcoat S, Pomeroy M, Sleweon S, Sami S, Ricaldi J, Gebru Y, et al.
- 517 Multistate Outbreak of SARS-CoV-2 B.1.1.529 (Omicron) Variant Infections Among
- 518 Persons in a Social Network Attending a Convention New York City, November 18–
- December 20, 2021. MMWR Morbidity and Mortality Weekly Report. 2022;71:238-42.
 Bendall EE, Callear AP, Getz A, Goforth K, Edwards D, Monto AS, et al. Rapid
- transmission and tight bottlenecks constrain the evolution of highly transmissible SARS CoV-2 variants. Nat Commun. 2023;14(1):272.
- Ji J, Viloria Winnett A, Shelby N, Reyes JA, Schlenker NW, Davich H, et al. Index
 cases first identified by nasal-swab rapid COVID-19 tests had more transmission to
 household contacts than cases identified by other test types. PLOS ONE.
- 526 2023;18(10):e0292389.
- 24. Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA:
 U.S. Department of Health and Human Services, CDC 2024 [15 April 2024]. Available
- 529 from: <u>https://covid.cdc.gov/covid-data-tracker/#vaccination-demographics-maps</u>.
- 530 25. Montgomery MP, Morris SE, Rolfes MA, Kittikraisak W, Samuels AM, Biggerstaff
- 531 M, et al. The role of asymptomatic infections in influenza transmission: what do we 532 really know. The Lancet Infectious Diseases.
- 26. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM,
- et al. Occurrence and transmission potential of asymptomatic and presymptomatic
- SARS-CoV-2 infections: A living systematic review and meta-analysis. PLOS Medicine.
 2020;17(9):e1003346.
- 537 27. Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P.
- 538 Estimating the extent of asymptomatic COVID-19 and its potential for community
- transmission: Systematic review and meta-analysis. J Assoc Med Microbiol Infect DisCan. 2020;5(4):223-34.
- 541 28. World Health Organization. Contact tracing and quarantine in the context of
- the Omicron SARS-CoV-2 variant. 2022.
- 29. Variation in the COVID-19 infection-fatality ratio by age, time, and geography
- during the pre-vaccine era: a systematic analysis. The Lancet. 2022;399(10334):1469-
- 545 **88**.

- 30. Xin H, Wang Z, Feng S, Sun Z, Yu L, Cowling BJ, et al. Transmission dynamics
 of SARS-CoV-2 Omicron variant infections in Hangzhou, Zhejiang, China, January February 2022. Int J Infect Dis. 2023;126:132-5.
- 549 31. Galmiche S, Cortier T, Charmet T, Schaeffer L, Chény O, von Platen C, et al.
- 550 SARS-CoV-2 incubation period across variants of concern, individual factors, and
- 551 circumstances of infection in France: a case series analysis from the ComCor study. 552 The Lancet Microbe. 2023;4(6):e409-e17.
- 553 32. Zeng K, Santhya S, Soong A, Malhotra N, Pushparajah D, Thoon KC, et al.
- 554 Serial Intervals and Incubation Periods of SARS-CoV-2 Omicron and Delta Variants, 555 Singapore. Emerg Infect Dis. 2023;29(4):814-7.
- 33. World Health Organization. Influenza Investigations & Studies (Unity Studies)
 2023 [Available from: <u>https://www.who.int/teams/global-influenza-</u>
- 558 programme/surveillance-and-monitoring/influenza-investigations-studies-unity.
- 559 34. World Health Organization. Respiratory Investigations and Studies (Unity
- 560 Studies) 2023 [Available from: <u>https://www.who.int/initiatives/respiratory-pathogens-</u> 561 <u>investigations-and-studies-unity-studies</u>.
- 562 35. Cope RC, Ross JV. Identification of the relative timing of infectiousness and
- symptom onset for outbreak control. Journal of Theoretical Biology. 2020;486:110079.
- 36. Klick B, Leung GM, Cowling BJ. Optimal design of studies of influenza
- transmission in households. I: Case-ascertained studies. Epidemiology and Infection.2012;140(1):106-14.
- 567 37. Lydeamore MJ, Campbell PT, Price DJ, Wu Y, Marcato AJ, Cuningham W, et al.
- Estimation of the force of infection and infectious period of skin sores in remote
 Australian communities using interval-censored data. PLOS Computational Biology.
 2020:16(10):e1007828
- 570 2020;16(10):e1007838.
 - 571 38. Lewis HC, Marcato AJ, Meagher N, Valenciano M, Villanueva-Cabezas JP,
 - 572 Spirkoska V, et al. Transmission of SARS-CoV-2 in standardised first few X cases and
 - 573 household transmission investigations: A systematic review and meta-analysis.
 - Influenza Other Respir Viruses. 2022;16(5):803-19.